June 13, 2022
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

SymBio announces status of market adoption of the 10-minuteRapid Infusion (RI) administration of the TREAKISYM® Liquid Formulation
TOKYO, Japan, June 13, 2022 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio")
today announced the status of market adoption of the rapid infusion (10-minute) administration ofTREAKISYM® 100mg/4mL liquid formulation (“TREAKISYM® RI administration”).
In September 2017, SymBio and Eagle Pharmaceuticals, Inc. (Headquarters: New Jersey, USA,“Eagle”) entered into a license agreement whereby SymBio obtained the exclusive rights to develop
and commercialize Eagle’s patent-protected liquid formulation of bendamustine hydrochloride(bendamustine HCl) in Japan. The Company launched TREAKISYM® 100mg/4mL ready-to-dilute(“RTD”) liquid formulation in Japan in January 2021. In February 2022, the Company received
approval of TREAKISYM® RI administration based on the results of its clinical study to investigate
the safety and pharmacokinetics of TREAKISYM® liquid formulation administered by 10-minuteintravenous drip infusion (Study 2018001) and studies on the safety of the 10-minute intravenous
drip infusion conducted outside Japan by Eagle (Study EGL-BDM-C-1301).
TREAKISYM® RI administration is identical to the product that is currently marketed in the UnitedStates under the trade name BENDEKA®, which was developed by Eagle as a formulation suitablefor 10-minute administration and approved in the United States by the Food and Drug
Administration (FDA) based on clinical studies conducted outside Japan. Compared to theconventional administration, TREAKISYM® RI administration has a lower infusion volume(approximately 50 ml vs. 250 ml) and a faster infusion time (10 minutes vs. 60 minutes). In addition
to the significant benefits to patients and healthcare professionals resulting from TREAKISYM® RI
administration’s reduced infusion time, the lower infusion volume means the infusion has lower saltcontent which benefits patients with dietary sodium restrictions.
As of the end of May 2022, the Company’s promotion plans for conversion of the market toTREAKISYM® RI administration were on track with 96% of major medical facilities reporting use ofTREAKISYM® RI administration and more than 94% of all medical facilities indicating theirintention to adopt TREAKISYM® RI administration.

1

SymBio does not expect the information presented herein to have any material impact on its financial
outlook for the fiscal year ending December 2022.

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125
About TREAKISYM® Liquid Formulation in the U.S. Market
In the United States, RI or the rapid infusion administration of bendamustine hydrochloride injection
was approved by the FDA in 2016 and is currently marketed in the U.S. by Teva PharmaceuticalIndustries, Ltd. (Headquarters: Israel, “Teva”) as BENDEKA® (bendamustine HCl) Injection. Sales infiscal 2018 amounted to approximately 65 billion yen.
About TREAKISYM®
TREAKISYM® (non-proprietary name: bendamustine hydrochloride), a cytocide anti-cancer drug firstused in Germany in the 1970s, is now widely used in more than 50 countries with indications for lowgrade non-Hodgkin’s lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia.
 TREAKISYM® Intravenous Infusion 100 mg was approved in October 2010 for manufacturing andmarketing for the indication of relapsed/refractory low-grade B-cell non-Hodgkin's lymphoma andmantle cell lymphoma in Japan.
 TREAKISYM® was approved for the additional indication of chronic lymphocytic leukemia in Japanin August 2016.
 TREAKISYM® was approved for the additional indications of first-line treatment of low-grade Bcell non-Hodgkin’s lymphoma and mantle cell lymphoma in Japan in December 2016.
 SymBio obtained approval for the marketing of TREAKISYM® Intravenous Drip Infusion
100mg/4mL (RTD, ready-to-dilute, liquid formulation) for all the above indications in September
2020.
 TREAKISYM® FD and RTD formulations were approved for the additional indication of relapsed orrefractory diffuse large B-cell lymphoma (r/r DLBCL) in March 2021 and April 2021, respectively.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who
previously served concurrently as Corporate VP of Amgen Inc. and founding President of AmgenJapan. In May 2016, SymBio incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma
USA, Inc. (Headquarters: Durham, North Carolina, President: Fuminori Yoshida). SymBio’s
underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading
global specialty biopharmaceutical company dedicated to address underserved medical needs.

2